| Trial ID: | L0522 |
| Source ID: | NCT05033054
|
| Associated Drug: |
Sglt2 Inhibitor
|
| Title: |
Effect of SGLT2i on Cardiovascular Biomarkers in Patients with Type 2 Diabetes and CKD Stage 3b-4
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Disease, Chronic|Diabetes
|
| Interventions: |
DRUG: SGLT2 inhibitor
|
| Outcome Measures: |
Primary: Change in serum klotho levels at 6 weeks, Change in serum klotho levels in participants with advanced Diabetic Kidney Disease (DKD) at 6 weeks are measured by immunoprecipitation-immunoblot., Baseline, 6 weeks|Change in serum klotho levels at 12 week, Change in Serum klotho levels in participants with advanced Diabetic Kidney Disease (DKD) at 12 weeks are measured by immunoprecipitation-immunoblot., Baseline, 12 weeks | Secondary: Change in serum magnesium levels at 6 weeks, Mean change from baseline in serum magnesium levels at 6 weeks is measured. Serum magnesium levels are measured by measuring the level of magnesium in the blood., Baseline, 6 weeks|Change in serum magnesium levels at 12 weeks, Mean change from baseline in serum magnesium levels at 12 weeks is measured. Serum magnesium levels are measured by measuring the level of magnesium in the blood., Baseline, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Texas Southwestern Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
28
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-01-01
|
| Completion Date: |
2025-06-30
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-20
|
| Locations: |
UT Southwestern Medical Center, Dallas, Texas, 75390, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05033054
|
